Atreca (NASDAQ:BCEL) Cut to Sell at BidaskClub

BidaskClub cut shares of Atreca (NASDAQ:BCEL) from a hold rating to a sell rating in a research report sent to investors on Thursday, BidAskClub reports.

A number of other analysts have also recently commented on BCEL. ValuEngine upgraded Atreca from a hold rating to a buy rating in a research report on Friday, July 17th. Zacks Investment Research lowered shares of Atreca from a buy rating to a hold rating in a research report on Monday, July 20th. Canaccord Genuity upped their price objective on shares of Atreca from $23.00 to $33.00 and gave the company a buy rating in a research note on Wednesday, July 1st. Robert W. Baird assumed coverage on shares of Atreca in a research note on Wednesday, April 15th. They issued an outperform rating and a $30.00 target price for the company. Finally, Cowen restated a buy rating on shares of Atreca in a report on Wednesday, June 17th. One analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company. The stock has a consensus rating of Buy and a consensus target price of $28.33.

Shares of BCEL opened at $12.95 on Thursday. Atreca has a 1-year low of $9.51 and a 1-year high of $29.35. The firm has a 50 day simple moving average of $18.56 and a 200-day simple moving average of $18.12.

Atreca (NASDAQ:BCEL) last announced its earnings results on Thursday, May 14th. The company reported ($0.73) EPS for the quarter, meeting analysts’ consensus estimates of ($0.73). As a group, sell-side analysts expect that Atreca will post -3.07 earnings per share for the current fiscal year.

In other Atreca news, Director William Hewitt Robinson sold 5,000 shares of the business’s stock in a transaction dated Monday, July 13th. The stock was sold at an average price of $20.23, for a total transaction of $101,150.00. Following the completion of the sale, the director now owns 412,542 shares of the company’s stock, valued at $8,345,724.66. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Norman Michael Greenberg sold 15,000 shares of the company’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $18.38, for a total value of $275,700.00. Following the sale, the insider now owns 15,000 shares of the company’s stock, valued at $275,700. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 92,472 shares of company stock worth $1,771,823. 9.90% of the stock is currently owned by insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Inc. grew its stake in Atreca by 42.0% during the first quarter. BlackRock Inc. now owns 1,863,589 shares of the company’s stock worth $30,841,000 after buying an additional 551,189 shares during the period. Goldman Sachs Group Inc. boosted its position in Atreca by 7.8% during the 4th quarter. Goldman Sachs Group Inc. now owns 396,321 shares of the company’s stock worth $6,132,000 after purchasing an additional 28,801 shares during the period. State Street Corp increased its holdings in Atreca by 142.2% in the 1st quarter. State Street Corp now owns 282,909 shares of the company’s stock valued at $4,682,000 after purchasing an additional 166,100 shares in the last quarter. Geode Capital Management LLC raised its position in Atreca by 89.6% in the first quarter. Geode Capital Management LLC now owns 171,116 shares of the company’s stock valued at $2,831,000 after purchasing an additional 80,874 shares during the period. Finally, Nuveen Asset Management LLC lifted its stake in shares of Atreca by 772.3% during the first quarter. Nuveen Asset Management LLC now owns 138,697 shares of the company’s stock worth $2,296,000 after purchasing an additional 122,797 shares in the last quarter. Hedge funds and other institutional investors own 62.14% of the company’s stock.

Atreca Company Profile

Atreca, Inc, a biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody in preclinical development with a novel mechanism of action and target derived from an antibody identified using its discovery platform.

Further Reading: Is it Safe to Invest in Commodities?

Analyst Recommendations for Atreca (NASDAQ:BCEL)

Receive News & Ratings for Atreca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atreca and related companies with MarketBeat.com's FREE daily email newsletter.